ImpactWayv™ Launches Social Media Platform Focused on Social Good
15.6.2021 16:00:00 EEST | Business Wire | Press release
ImpactWayv, Inc. today announced the public launch of its pioneering social media platform, ImpactWayv™, which is now available to download on the Apple App Store. The new platform’s focus is to connect people, businesses and philanthropy for social good.
Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv was created to drive collective impact across causes and communities. The platform operates as an entirely new kind of digital ecosystem, enabling users to effect, engage in and share social impact on a global scale.
Users of ImpactWayv will be able to connect and interact with each other through each of its core components, including:
- Public and private personal networks and content feeds to engage with and create impact.
- The “Impact Market” – a public exchange of transparent impact profiles of businesses and nonprofits for all to compare, follow, engage with and directly support.
- “Wayvs” (social impact causes, topics, trends and broader issue areas) – an organizing framework for purpose-driven content and information across the platform.
“ImpactWayv is democratizing social impact for all,” said Dan Rubino, Co-Founder, Chairman and Chief Executive Officer of ImpactWayv, Inc. “Finally, there is a purpose-built social media platform that gives consumers, brands, businesses and nonprofits a way to explore, create, engage and transact across all categories of daily life, with more meaning, more purpose and more goodwill.”
Engagement on the platform is driven by dozens of Wayvs™ ranging across social impact cause areas and covering various topics relating to the interplay of business, philanthropy and individual effort to drive social good. Some examples include Climate Action; Diversity, Equity and Inclusion (DE&I); Corporate Social Responsibility (CSR); Human Rights; Public Health; Environmental, Social and Governance (ESG); Voter Registration; and Renewable Energy. Wayvs facilitate and encourage user discoverability and engagement across the platform. Users tap them to find relevant impact discussions and initiatives, as well as like-minded individuals, companies and nonprofits that share their commitment to the causes they care about.
“An unprecedented interest in social action has been building globally for some time, further accelerated and focused by recent events,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “People need a way to explore and express their values. Businesses need to use their resources and influence to make things better. And nonprofits need to leverage their missions for maximum effectiveness. ImpactWayv meets this unique moment in time by linking people and organizations around the world on a deeper level.”
To catalyze user engagement, ImpactWayv also created a groundbreaking tool to measure a user’s impact on their digital community, through the platform’s signature “Impact” metric, which tracks a user’s positive “ripple effect” across the platform, in real time.
“Our ambition at ImpactWayv is to disrupt and transform the worlds of business and philanthropy through technology,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “Through our extraordinary blend of seasoned leaders and trailblazers in the worlds of corporate purpose, philanthropy and technology, we believe we have created a powerful business model that will advance universal social good.”
ImpactWayv is now available for free download on the Apple App Store and will be available on Google Play and other non-iOS devices later this year. Companies and nonprofits are also invited to contact ImpactWayv to become a member of the platform, which will enable them to claim their profile, initiate an engagement strategy on ImpactWayv and become a “Featured Organization” on the platform.
About ImpactWayv, Inc.
ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information, please visit: www.impactwayv.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005331/en/
Contact information
Media
Jonathan Younger
214-259-3426
jonathan.younger@ketchum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
